TrialDiabetes, obesity & metabolism2017

Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.

Steven G Terra et al.PubMed ↗Publisher ↗

No numbers read from the abstract.